Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Premarin reference · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Premarin reference tablet as a single oral dose under fasted conditions |
| B | EXPERIMENTAL | Premarin new tablet as a single oral dose under fasted conditions |
| C | EXPERIMENTAL | Premarin reference tablet as a single oral dose under fed conditions |
| D | EXPERIMENTAL | Premarin new tablet as a single oral dose under fed conditions |
| Name | Type | Description |
|---|---|---|
| Premarin reference tablet (fasted) | DRUG | Premarin reference tablet, single dose, fasted conditions |
| Premarin new tablet (fasted) | DRUG | Premarin new tablet, single dose, fasted conditions |
| Premarin reference tablet (fed) | DRUG | Premarin reference tablet, single dose, fed conditions |
| Premarin new tablet (fed) | DRUG | Premarin new tablet, single dose, fed conditions |
Inclusion Criteria: * Japanese healthy postmenopausal women Exclusion Criteria: * History or current evidence of thrombophlebitis, thromboembolic disorders, or any coagulopathies. * History or presence of malignancy or estrogen-dependent neoplasia. Subjects with a documented history of any malign...
Premarin is a small molecule drug being developed by Pfizer for use in postmenopause, primary ovarian insufficiency, and menopause. It is currently in Phase 1 clinical development, meaning it is investigational and not yet approved for these uses.
Premarin is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials for postmenopause, primary ovarian insufficiency, and menopause.
Premarin is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. All three completed clinical trials for Premarin were Phase 1 studies, and there are no active trials currently ongoing.
Premarin has completed three Phase 1 clinical trials. These include NCT00543634, comparing Premarin with MPA, PREMPRO, and Provera in healthy postmenopausal women; NCT00630435, comparing new formulations of Premarin with a reference formulation; and NCT00745173, evaluating a potential interaction between Premarin and bazedoxifene.
Premarin is not the same as PREMPRO, though they are related. PREMPRO is a combination product that contains Premarin (conjugated estrogens) and MPA (medroxyprogesterone acetate). Clinical trial NCT00543634 directly compared Premarin with MPA, PREMPRO, and Provera in healthy postmenopausal women.